These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 33607174)

  • 1. Evolution of mathematical models of cardiomyocyte electrophysiology.
    Amuzescu B; Airini R; Epureanu FB; Mann SA; Knott T; Radu BM
    Math Biosci; 2021 Apr; 334():108567. PubMed ID: 33607174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive in vitro Proarrhythmia Assay, a novel in vitro/in silico paradigm to detect ventricular proarrhythmic liability: a visionary 21st century initiative.
    Cavero I; Holzgrefe H
    Expert Opin Drug Saf; 2014 Jun; 13(6):745-58. PubMed ID: 24845945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Introduction to Computational Modeling of Cardiac Electrophysiology and Arrhythmogenicity.
    Mayourian J; Sobie EA; Costa KD
    Methods Mol Biol; 2018; 1816():17-35. PubMed ID: 29987808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac voltage-gated ion channels in safety pharmacology: Review of the landscape leading to the CiPA initiative.
    Huang H; Pugsley MK; Fermini B; Curtis MJ; Koerner J; Accardi M; Authier S
    J Pharmacol Toxicol Methods; 2017 Sep; 87():11-23. PubMed ID: 28408211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CiPA challenges and opportunities from a non-clinical, clinical and regulatory perspectives. An overview of the safety pharmacology scientific discussion.
    Wallis R; Benson C; Darpo B; Gintant G; Kanda Y; Prasad K; Strauss DG; Valentin JP
    J Pharmacol Toxicol Methods; 2018; 93():15-25. PubMed ID: 29958940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computational modeling for cardiac safety pharmacology analysis: Contribution of fibroblasts.
    Gao X; Engel T; Carlson BE; Wakatsuki T
    J Pharmacol Toxicol Methods; 2017 Sep; 87():68-73. PubMed ID: 28456609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Computational modeling of cardiac electrophysiology and arrhythmogenesis: toward clinical translation.
    Trayanova NA; Lyon A; Shade J; Heijman J
    Physiol Rev; 2024 Jul; 104(3):1265-1333. PubMed ID: 38153307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recording of multiple ion current components and action potentials in human induced pluripotent stem cell-derived cardiomyocytes via automated patch-clamp.
    Mann SA; Heide J; Knott T; Airini R; Epureanu FB; Deftu AF; Deftu AT; Radu BM; Amuzescu B
    J Pharmacol Toxicol Methods; 2019; 100():106599. PubMed ID: 31228558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of an In Silico Mechanistic Model for Proarrhythmia Risk Prediction Under the CiPA Initiative.
    Li Z; Ridder BJ; Han X; Wu WW; Sheng J; Tran PN; Wu M; Randolph A; Johnstone RH; Mirams GR; Kuryshev Y; Kramer J; Wu C; Crumb WJ; Strauss DG
    Clin Pharmacol Ther; 2019 Feb; 105(2):466-475. PubMed ID: 30151907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CiPA: Ongoing testing, future qualification procedures, and pending issues.
    Cavero I; Holzgrefe H
    J Pharmacol Toxicol Methods; 2015; 76():27-37. PubMed ID: 26159293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative Systems Pharmacology Models for a New International Cardiac Safety Regulatory Paradigm: An Overview of the Comprehensive In Vitro Proarrhythmia Assay In Silico Modeling Approach.
    Li Z; Garnett C; Strauss DG
    CPT Pharmacometrics Syst Pharmacol; 2019 Jun; 8(6):371-379. PubMed ID: 31044559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative - Update on progress.
    Colatsky T; Fermini B; Gintant G; Pierson JB; Sager P; Sekino Y; Strauss DG; Stockbridge N
    J Pharmacol Toxicol Methods; 2016; 81():15-20. PubMed ID: 27282641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiomyocyte calcium handling in health and disease: Insights from in vitro and in silico studies.
    Sutanto H; Lyon A; Lumens J; Schotten U; Dobrev D; Heijman J
    Prog Biophys Mol Biol; 2020 Nov; 157():54-75. PubMed ID: 32188566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrative Computational Modeling of Cardiomyocyte Calcium Handling and Cardiac Arrhythmias: Current Status and Future Challenges.
    Sutanto H; Heijman J
    Cells; 2022 Mar; 11(7):. PubMed ID: 35406654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute effects of alcohol on cardiac electrophysiology and arrhythmogenesis: Insights from multiscale in silico analyses.
    Sutanto H; Cluitmans MJM; Dobrev D; Volders PGA; Bébarová M; Heijman J
    J Mol Cell Cardiol; 2020 Sep; 146():69-83. PubMed ID: 32710981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive in vitro Proarrhythmia Assay (CiPA): Pending issues for successful validation and implementation.
    Cavero I; Guillon JM; Ballet V; Clements M; Gerbeau JF; Holzgrefe H
    J Pharmacol Toxicol Methods; 2016; 81():21-36. PubMed ID: 27233533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uncertainty Quantification Reveals the Importance of Data Variability and Experimental Design Considerations for
    Chang KC; Dutta S; Mirams GR; Beattie KA; Sheng J; Tran PN; Wu M; Wu WW; Colatsky T; Strauss DG; Li Z
    Front Physiol; 2017; 8():917. PubMed ID: 29209226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proarrhythmia liability assessment and the comprehensive in vitro Proarrhythmia Assay (CiPA): An industry survey on current practice.
    Authier S; Pugsley MK; Koerner JE; Fermini B; Redfern WS; Valentin JP; Vargas HM; Leishman DJ; Correll K; Curtis MJ
    J Pharmacol Toxicol Methods; 2017 Jul; 86():34-43. PubMed ID: 28223123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive In Vitro Proarrhythmia Assay (CiPA) Update from a Cardiac Safety Research Consortium / Health and Environmental Sciences Institute / FDA Meeting.
    Strauss DG; Gintant G; Li Z; Wu W; Blinova K; Vicente J; Turner JR; Sager PT
    Ther Innov Regul Sci; 2019 Jul; 53(4):519-525. PubMed ID: 30157676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A general procedure to select calibration drugs for lab-specific validation and calibration of proarrhythmia risk prediction models: An illustrative example using the CiPA model.
    Han X; Samieegohar M; Ridder BJ; Wu WW; Randolph A; Tran P; Sheng J; Stoelzle-Feix S; Brinkwirth N; Rotordam MG; Becker N; Friis S; Rapedius M; Goetze TA; Strassmaier T; Okeyo G; Kramer J; Kuryshev Y; Wu C; Strauss DG; Li Z
    J Pharmacol Toxicol Methods; 2020 Sep; 105():106890. PubMed ID: 32574700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.